(A) Disease-free (ie, relapse-free) and (B) overall survival of patients age ≥ 60 years with CN de novo AML according to NPM1 mutation status. (C) The same as (A), but including only patients age ≥ 70. (D) The same as (B), but including only patients age ≥ 70.